Last updated: February 13, 2026
What is the current market status for NDC 00168-0099?
NDC 00168-0099 is the National Drug Code for Humira (adalimumab), a biologic used primarily for autoimmune diseases including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. As of 2023, Humira remains a top-selling biologic worldwide with over $21 billion in global sales in 2022, according to IQVIA.
Market landscape
- Market penetration: Humira holds approximately 9% of the global biologics market for autoimmune diseases.
- Competitors: Enters with biosimilars such as Amgen’s Amgevita, Samsung’s Hadlima, and newer options including Skyrizi and Cosentyx.
- Patent expiry: U.S. patents expired in January 2023; key European patents expired in 2023, paving the way for biosimilar competition.
What are the current price points and reimbursement landscape?
Typical list and net prices
- List price (U.S.): Approximately $6,000 per 40 mg dose.
- Average selling price (ASP): Around $4,300 per injection after rebates and discounts, based on IQVIA data.
- Reimbursement factors: Payers negotiate discounts, affecting actual transaction prices.
Biosimilar impact
- Price reduction: Biosimilars initially priced 15–30% below reference product.
- Market share: Biosimilars account for roughly 20% of Humira prescriptions in the U.S. by late 2023, with expectations to increase.
How is the market expected to evolve?
Short-term outlook (2023-2025)
- Biosimilar proliferation: Predicted to capture 50% of the US Humira market by end of 2024.
- Pricing pressure: List prices could decline by 15-20% as biosimilars gain market share.
- Reimbursement shifts: Payers increasingly favor biosimilars, actual patient out-of-pocket costs may decrease.
Long-term projection (2026+)
- Market contraction: Revenues for Humira are expected to decline as biosimilars dominate.
- Innovator strategies: Original manufacturer might focus on new formulations, delivery methods, or expanded indications to maintain revenue.
Exogenous factors
- Regulatory delays: Any further patent litigations or delays influence timing for biosimilar proliferation.
- Policy changes: Rebate reforms or price controls could further pressure prices.
Price projection estimates
| Year |
List Price (USD) |
Net Price (USD) |
Market Share of Biosimilars |
Commentary |
| 2023 |
$6,000 |
$4,300 |
20% |
Biosimilar entry begins significantly impacting prices and market share. |
| 2024 |
$5,800 |
$4,100 |
50% |
Biosimilar adoption accelerates, overall revenue declines. |
| 2025 |
$5,400 |
$3,800 |
65% |
Biosimilar dominance increases, pricing continues to decline. |
| 2026 |
$5,200 |
$3,600 |
75% |
Market stabilizes with biosimilars holding major share. |
Note: These projections assume continued biosimilar rollout, payer negotiations, and no significant regulatory or manufacturing disruptions.
Key factors influencing market and pricing
- Patent litigation: Extended legal battles could delay biosimilar uptake.
- Manufacturing capacity: Biosimilar producers’ ability to meet demand affects pricing and market share.
- Regulatory environment: Favorable policies promote biosimilar integration, driving down prices.
- Therapeutic innovation: New formulations or indications can sustain patent exclusivity.
Summary
Humira (NDC: 00168-0099) remains a leading biologic, but its revenue is under sustained pressure from biosimilar competition. Prices are projected to decline gradually over the next three years, with significant market share shifts favoring biosimilars. Long-term, revenue decline is expected as biosimilars dominate, although manufacturer innovation could mitigate losses.
Key Takeaways
- Humira’s U.S. list price stands around $6,000 per dose; net prices are approximately $4,300.
- Biosimilars gained 20% market share by late 2023, with projections reaching 75% by 2026.
- Prices are expected to decrease by approximately 15-20% over the next two years due to biosimilar competition.
- Revenue decline will accelerate post-2025 unless new indications or formulations extend patent life.
- Policy developments and patent disputes remain critical factors influencing future market dynamics.
FAQs
1. How quickly will biosimilars erode Humira’s market share?
Biosimilars are projected to capture 50% of the U.S. market by the end of 2024, with a dominant share by 2026.
2. Will the list price of Humira decrease?
Yes, list prices are expected to decline by 15–20% over the next two years as biosimilar competition intensifies.
3. Are biosimilars priced similarly worldwide?
No, prices vary significantly by region. Developed markets like Europe see lower biosimilar prices relative to the U.S., often around 30–50% below reference.
4. Can the original manufacturer counter biosimilar threats?
Yes, through new patent filings, developing improved formulations, or expanding indications that can extend market exclusivity.
5. What regulatory factors could alter the projected landscape?
Patent litigation delays or changes in biosimilar approval pathways can slow biosimilar entry or affect pricing.
Sources:
- IQVIA. (2023). Biotech and biosimilar market data.
- FDA. (2023). Biosimilar approval and patent data.
- EvaluatePharma. (2022). Top-selling biologics report.
- Amgen. (2023). Biosimilar market entry and pricing.
- Statista. (2023). Biologic market statistics.
